When a biotech story has to travel without its founder (ProTGen)

What happens when a breakthrough biotech company outgrows its founder’s ability to personally tell the story?In this episode, we explore a challenge facing many science-led startups: the transition from a founder-carried narrative to a market-carried narrative. Using ProTGen as a case study, we unpack why the next stage of growth requires more than a polished pitch deck, refreshed website, or redesigned one-pager. It requires what we call portable conviction. We discuss:Why great science often suffers from having too many compelling storiesThe difference between explaining a company and creating belief in a companyHow investors, partners, and stakeholders process complex scientific narrativesThe critical role of narrative sequencing: problem → solution → proof → platformWhy ProT-096 should serve as a bridge between today's clinical reality and tomorrow's platform opportunityHow manufacturing, partnerships, and operational milestones become credibility-building proof pointsThe concept of a "story spine" and why every communication asset should flow from itPractical ways to test whether your story is clear, memorable, and retellableAlong the way, we examine a fundamental strategic question: What should your audience believe first?Whether you're a biotech founder, investor, innovation leader, or strategist working with complex technologies, this conversation offers a framework for transforming scientific complexity into market conviction.Because the ultimate goal isn't creating better materials.It's building a story that can walk into the room on its own.